Canopy Growth stock rises on Trump’s marijuana regulation easing plans
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 20 2024
0mins
Should l Buy CGC?
Canopy Growth Corp's stock surged by 23.89%, reaching a 20-day high, amid a broader market decline with the Nasdaq-100 down 1.49% and the S&P 500 down 0.78%.
This increase is attributed to reports that President Donald Trump plans to ease federal restrictions on marijuana, which has led to a significant rise in cannabis stocks, including Canopy Growth. The potential reclassification of marijuana as a Schedule III drug could attract more investment in the cannabis industry and allow banks to service cannabis companies more effectively.
The implications of this news suggest a shift in the regulatory landscape for cannabis, which could lead to increased market activity and investment opportunities in the sector, despite the overall struggles of cannabis stocks in the past year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CGC
Wall Street analysts forecast CGC stock price to rise
4 Analyst Rating
1 Buy
2 Hold
1 Sell
Hold
Current: 1.120
Low
1.03
Averages
2.52
High
5.90
Current: 1.120
Low
1.03
Averages
2.52
High
5.90
About CGC
Canopy Growth Corporation is a Canada-based cannabis company. The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company delivers innovative products from owned and licensed brands, including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. Its segments include Canada cannabis, and Storz & Bickel. Its Canada cannabis segment includes the production, distribution, and sale of a range of cannabis, hemp, and cannabis related products in Canada. Its Storz & Bickel segment includes the production, distribution, and sale of vaporizers. In addition, it serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Investment Risks in Canopy Growth Stock
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to its current price of $1.15, resulting in significant paper losses for investors, indicating a dramatic decline in enthusiasm for marijuana investments that necessitates a reassessment of holding strategies.
- Shareholder Dilution Risk: The rapid expansion of Canopy Growth's share count raises concerns about shareholder dilution, further impacting its market appeal and investor confidence, which may lead to increased sell-offs by investors.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolios, thereby reducing tax liabilities; this strategy is commonly employed by savvy individual and institutional investors alike.
- Uncertain Future Outlook: While some investors hope for a rebound in Canopy Growth's fortunes, the current financial performance and market conditions heighten the risks associated with holding the stock, prompting investors to carefully consider whether to maintain their positions to avoid further losses.
See More
Canopy Growth Faces Significant Losses
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to just over $1 now, leaving investors with significant paper losses and indicating a dramatic decline in enthusiasm for the marijuana sector.
- Profitability Struggles: As a money-losing penny stock, Canopy Growth's ongoing losses and expanding share count raise concerns about shareholder dilution, highlighting major challenges in its business model.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolio, showcasing the flexibility of investment strategies to mitigate tax burdens.
- Investment Advice: Canopy Growth was not included in the Motley Fool analyst team's list of the 10 best stocks, reflecting a pessimistic outlook on its future performance, prompting investors to carefully consider whether to hold onto the stock.
See More
Altria's Transformation and Challenges Ahead
- Declining Revenue Trend: Altria's total net revenue fell by 3% in 2025 to $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although the company continues to maintain high margins and strong cash flow.
- Transformation Strategy: The company is implementing its 'Moving Beyond Smoking' strategy, aiming to become a smoke-free product supplier by 2030, despite facing significant setbacks in electronic cigarettes and oral tobacco products due to a patent infringement lawsuit, highlighting the challenges of this transition.
- Dividend Appeal: Altria is dubbed a 'Dividend King' with a 56-year streak of dividend increases, recently raising its quarterly dividend to $4.24 per share, yielding 6.3%, which provides an attractive option for income-seeking investors.
- Market Uncertainty: While Altria faces challenges in its transformation process, it continues to attract investors through strong dividend returns; however, the future market environment and the progress of its transition remain uncertain.
See More
Altria's Transition Path Amidst Industry Challenges
- Revenue Decline: Altria's total net revenue fell by 3% in 2025 to under $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although it maintains a high gross margin of 75.83%.
- Dividend King Status: In mid-2025, Altria raised its quarterly dividend by 4% to $4.24 per share, yielding 6.3%, which keeps it competitive in the high-yield sector and attracts income-focused investors.
- Transition Challenges: While Altria aims to become a smoke-free product provider by 2030, its recent patent infringement loss highlights uncertainties in its transition, with smokeable products still accounting for 88% of net revenue.
- Strong Cash Flow: Last year, Altria generated over $9 billion in free cash flow, marking the second-highest level in five years, ensuring the company can continue its dividend payments and fund future investments.
See More
Canopy Growth's Stock Plummets 95%, High-Risk Investment
- Stock Price Collapse: Canopy Growth's stock has plummeted over 95% since its IPO, dropping from over $560 in 2019 to just $1.15 today, indicating the company's failure to meet Wall Street's high expectations, severely undermining investor confidence.
- Ongoing Losses: Despite being public for nearly a decade, Canopy Growth has yet to post a profit, with continuous financial losses leading to investor disappointment and exacerbating its status as a penny stock, which is inherently high-risk.
- Capital Restructuring: The company announced a recapitalization of its balance sheet in late 2025, which, while positive, highlights its weak financial condition; the issuance of warrants to bondholders could lead to shareholder dilution, further complicating its financial outlook.
- Acquisition of MTL Cannabis: Canopy Growth is moving forward with the acquisition of MTL Cannabis, despite both companies being unprofitable; this cash-and-stock deal will strain its balance sheet and increase shareholder dilution risk, potentially jeopardizing its long-term sustainability.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
Analysis of Investment Risks in Canopy Growth Stock
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to its current price of $1.15, resulting in significant paper losses for investors, indicating a dramatic decline in enthusiasm for marijuana investments that necessitates a reassessment of holding strategies.
- Shareholder Dilution Risk: The rapid expansion of Canopy Growth's share count raises concerns about shareholder dilution, further impacting its market appeal and investor confidence, which may lead to increased sell-offs by investors.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolios, thereby reducing tax liabilities; this strategy is commonly employed by savvy individual and institutional investors alike.
- Uncertain Future Outlook: While some investors hope for a rebound in Canopy Growth's fortunes, the current financial performance and market conditions heighten the risks associated with holding the stock, prompting investors to carefully consider whether to maintain their positions to avoid further losses.
See More
Canopy Growth Faces Significant Losses
- Stock Price Plunge: Canopy Growth's stock has fallen from a peak of $568 in 2018 to just over $1 now, leaving investors with significant paper losses and indicating a dramatic decline in enthusiasm for the marijuana sector.
- Profitability Struggles: As a money-losing penny stock, Canopy Growth's ongoing losses and expanding share count raise concerns about shareholder dilution, highlighting major challenges in its business model.
- Tax Loss Harvesting: Investors can realize tax losses by selling Canopy Growth shares, allowing them to offset capital gains elsewhere in their portfolio, showcasing the flexibility of investment strategies to mitigate tax burdens.
- Investment Advice: Canopy Growth was not included in the Motley Fool analyst team's list of the 10 best stocks, reflecting a pessimistic outlook on its future performance, prompting investors to carefully consider whether to hold onto the stock.
See More
Altria's Transformation and Challenges Ahead
- Declining Revenue Trend: Altria's total net revenue fell by 3% in 2025 to $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although the company continues to maintain high margins and strong cash flow.
- Transformation Strategy: The company is implementing its 'Moving Beyond Smoking' strategy, aiming to become a smoke-free product supplier by 2030, despite facing significant setbacks in electronic cigarettes and oral tobacco products due to a patent infringement lawsuit, highlighting the challenges of this transition.
- Dividend Appeal: Altria is dubbed a 'Dividend King' with a 56-year streak of dividend increases, recently raising its quarterly dividend to $4.24 per share, yielding 6.3%, which provides an attractive option for income-seeking investors.
- Market Uncertainty: While Altria faces challenges in its transformation process, it continues to attract investors through strong dividend returns; however, the future market environment and the progress of its transition remain uncertain.
See More
Altria's Transition Path Amidst Industry Challenges
- Revenue Decline: Altria's total net revenue fell by 3% in 2025 to under $23.3 billion, indicating a weakening reliance on the traditional cigarette market, although it maintains a high gross margin of 75.83%.
- Dividend King Status: In mid-2025, Altria raised its quarterly dividend by 4% to $4.24 per share, yielding 6.3%, which keeps it competitive in the high-yield sector and attracts income-focused investors.
- Transition Challenges: While Altria aims to become a smoke-free product provider by 2030, its recent patent infringement loss highlights uncertainties in its transition, with smokeable products still accounting for 88% of net revenue.
- Strong Cash Flow: Last year, Altria generated over $9 billion in free cash flow, marking the second-highest level in five years, ensuring the company can continue its dividend payments and fund future investments.
See More
Canopy Growth's Stock Plummets 95%, High-Risk Investment
- Stock Price Collapse: Canopy Growth's stock has plummeted over 95% since its IPO, dropping from over $560 in 2019 to just $1.15 today, indicating the company's failure to meet Wall Street's high expectations, severely undermining investor confidence.
- Ongoing Losses: Despite being public for nearly a decade, Canopy Growth has yet to post a profit, with continuous financial losses leading to investor disappointment and exacerbating its status as a penny stock, which is inherently high-risk.
- Capital Restructuring: The company announced a recapitalization of its balance sheet in late 2025, which, while positive, highlights its weak financial condition; the issuance of warrants to bondholders could lead to shareholder dilution, further complicating its financial outlook.
- Acquisition of MTL Cannabis: Canopy Growth is moving forward with the acquisition of MTL Cannabis, despite both companies being unprofitable; this cash-and-stock deal will strain its balance sheet and increase shareholder dilution risk, potentially jeopardizing its long-term sustainability.
See More
Weekly Roundup: Cannabis and Psychedelic Sector Developments
- Organigram Strategic Investment: Organigram announced a C$65.2 million investment agreement with British American Tobacco to support its acquisition of Germany's Sanity Group, which is expected to position the company as a leader in the global legal cannabis market and expand its commercial footprint.
- Canopy Growth Acquisition Progress: Canopy Growth's acquisition plan for MTL Cannabis received 99.97% shareholder support, which is projected to enhance its leadership in the Canadian medical cannabis market and improve supply chain efficiency through the integration of MTL's patient network and cultivation facilities.
- Green Thumb Financing Expansion: Green Thumb Industries secured an additional $50 million credit facility from Valley National Bank, bringing its total to $189 million, which is expected to be used for strategic investments and working capital, further solidifying its market position.
- Enveric New Data Release: Enveric Biosciences reported new findings on EB-003, highlighting its non-hallucinogenic neuroplasticity strategy's effectiveness, potentially offering new options for depression and anxiety treatment, thus driving the company's innovation in mental health solutions.
See More
